The supplement adulterant β-methylphenethylamine (BMPEA, 2-phenylpropan-1-amine) increases blood pressure by acting at peripheral norepinephrine transporters

Charles W. Schindler, Eric B. Thorndike, Kenner C. Rice, John S. Partilla and Michael H. Baumann

Designer Drug Research Unit (C.W.S., J.S.P, M.H.B.), Preclinical Pharmacology Section (E.B.T), NIDA, Intramural Research Program, Baltimore, MD and Drug Design and Synthesis Section (K.C.R.), NIDA and NIAAA Intramural Research Programs, Rockville, MD
Running Title Page

Running Title: Pharmacology of β-methylphenethylamine and its analogs

Corresponding Author: Charles W. Schindler
Designer Drug Research Unit
NIH/NIDA Intramural Research Program
251 Bayview Blvd.
Baltimore, MD 21224
(443) 740-2520
cschind@helix.nih.gov

Text Pages: 16
Tables: 2
Figures: 6
References:
Abstract: 244
Introduction: 549
Discussion: 1738

Recommended Section: Cardiovascular

Abbreviations: BMPEA, β-methylphenethylamine; MPPA, N-methyl-2-phenylpropan-1-amine; DMPPA, N,N-dimethyl-2-phenylpropan-1-amine; DAT, dopamine transporter; GBR12909, 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine; MPP⁺, methyl-4-phenylpyridinium; NET, norepinephrine transporter; SERT, serotonin transporter
Abstract

β-Methylphenethylamine (BMPEA, 2-phenylpropan-1-amine) is a structural isomer of amphetamine (1-phenylpropan-2-amine) that has been identified in pre-workout and weight loss supplements, yet little information is available about its pharmacology. Here, the neurochemical and cardiovascular effects of BMPEA and its analogs, N-methyl-2-phenylpropan-1-amine (MPPA) and N,N-dimethyl-2-phenylpropan-1-amine (DMPPA), were compared to structurally-related amphetamines. As expected, amphetamine and methamphetamine were potent substrate-type releasing agents at transporters for dopamine (DAT) and norepinephrine (NET) in rat brain synaptosomes. BMPEA and MPPA were also substrates at DAT and NET but they were at least 10-fold less potent than amphetamine. DMPPA was a weak substrate only at NET. Importantly, the releasing actions of BMPEA and MPPA were more potent at NET than DAT. Amphetamine produced significant dose-related increases in blood pressure (BP), heart rate (HR), and locomotor activity in conscious rats fitted with surgically-implanted biotelemetry transmitters. BMPEA, MPPA and DMPPA produced increases in BP that were similar to the effects of amphetamine, but the compounds failed to substantially affect HR or activity. The hypertensive effect of BMPEA was reversed by the α-adrenergic antagonist prazosin but not the ganglionic blocker chlorisondamine. Radioligand binding at various G protein-coupled receptors did not identify non-transporter sites of action which could account for cardiovascular effects of BMPEA or its analogs. Our results show that BMPEA, MPPA and DMPPA are biologically active. The compounds are unlikely to be abused due to weak effects at DAT, but they could produce adverse cardiovascular effects via substrate activity at peripheral NET sites.

Keywords: blood pressure, dopamine, norepinephrine, supplements, transporter
Introduction

Dietary supplements are used by a significant portion of the population, and many supplement products contain ingredients that are not properly listed on the label. The phenomenon of unlisted ingredients is well established for supplements that are promoted for body building and performance enhancement (i.e., pre-workout supplements) (Eichner et al., 2016; Rasmussen and Keizers, 2016). As a specific example, pre-workout supplements that list the Southwestern scrub plant *Acacia rigidula* as an ingredient often contain β-methylphenethyamine (BMPEA, 2-phenylpropan-1-amine), a structural isomer of amphetamine (1-phenylpropan-2-amine). BMPEA was first described in the 1930s as a sympathomimetic agent (Cohen et al., 2016). While the manufacturers of pre-workout supplements claim that *Acacia rigidula* is a natural source of BMPEA, there is no evidence to support this assertion (Cohen et al., 2015). Thus, the US Food and Drug Administration (FDA) concluded that products containing BMPEA were adulterated and banned their sale in 2015 (Pawar and Grundel, 2015). Despite the fact that BMPEA and related adulterants are banned by the FDA, chemical analogs often still appear in supplement products (Eichner et al., 2016). Many of these compounds have not been fully tested for safety, and as a result, individuals using these supplements may be at risk for serious medical complications (Venhuis et al., 2014).

Cohen et al. (2015) reported the case of a woman who ingested a sports supplement 30 min before exercise and subsequently experienced “numbness and clumsiness in her left hand.” The patient reported taking no other drugs prior to exercise. A computed tomography scan revealed she had a “2-cm hemorrhage in the right parietal lobe”. Forensic analysis of the ingested supplement determined that it contained BMPEA at a level of 290 mg when used at the recommended amount. While the pharmacology of BMPEA has not been investigated in
humans, older studies from around the time of its original synthesis show it can increase blood pressure (BP) in dogs (Graham et al., 1945; Marsh, 1948; Winder et al., 1948), rabbits (Hartung and Munch, 1931; Warren et al., 1943) and rats (Graham and Cartland, 1944). Therefore, it seems feasible that hypertension following the ingestion of the supplement containing BMPEA contributed to the occurrence of hemorrhagic stroke described by Cohen and colleagues (2015).

As noted above, the FDA banned the addition of BMPEA to supplements in 2015, but BMPEA and related compounds are still found in certain supplement products (Cohen et al., 2016; Rasmussen and Keizers, 2016). Because these compounds are structurally-related to amphetamine, it seems possible that they have pharmacological and toxic effects similar to amphetamine and other stimulants. Here, we studied the pharmacology of BMPEA and its secondary (N-methyl-2-phenylpropan-1-amine, MPPA) and tertiary (N,N-dimethyl-2-phenylpropan-1-amine, DMPPA) amine analogs (see Figure 1 for chemical structures). For comparison, we also investigated amphetamine and its secondary (N-methyl-1-phenylpropan-2-amine, methamphetamine) and tertiary (N,N-dimethyl-1-phenylpropan-2-amine, dimethylamphetamine) amine analogs. All compounds were first evaluated for substrate-type releasing activity at transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT) using in vitro functional assays in rat brain synaptosomes. BMPEA and its analogs were also tested for binding affinity at various G protein-coupled receptors (GPCRs) using in vitro assays in cells transfected with human receptors. Finally, the in vivo effects of systemically-administered BMPEA and its analogs were examined in rats fitted with surgically-implanted biotelemetry transmitters to measure BP, heart rate (HR), temperature and locomotor activity.

**Materials and Methods**
All procedures reported here were approved by the NIDA/IRP Animal Care and Use Committee and followed the guidelines described in the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011). Animals were housed in facilities fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.

**Drugs and reagents**

The β-methyl compounds 2-phenylpropan-1-amine (BMPEA) and N-methyl-2-phenylpropan-1-amine (MPPA) were synthesized as fumarate salts, whereas N,N-dimethyl-2-phenylpropan-1-amine (DMPPA), was synthesized as the HCl salt. BMPEA, MPPA and DMPPA were synthesized using standard organic chemical reactions and techniques. Each compound was fully characterized by high resolution mass spectral and 400 MHz NMR analyses and gave appropriate combustion analyses for carbon, hydrogen and nitrogen. Each compound was chromatographically homogenous by thin layer chromatography. Chemical purity for each compound was estimated to be greater than 98%. The corresponding α-methyl comparator compounds (S)-amphetamine sulfate (amphetamine), (S)-methamphetamine HCl (methamphetamine) and racemic N,N-dimethylamphetamine HCl (dimethylamphetamine) were obtained from the NIDA/IRP Pharmacy in Baltimore, MD. [^3H]Methyl-4-phenylpyridinium ([^3H]MPP^+; 80 Ci/mmol) was purchased from American Radiolabeled Chemicals (St. Louis, MO, USA) while [^3H]5-HT (38 Ci/mmol) was purchased from Perkin Elmer (Billerica, MA, USA). All other chemicals and reagents were acquired from Sigma-Aldrich (St Louis, MO, USA) unless otherwise noted.

*In vitro transporter release assays in synaptosomes*
Adult male Sprague-Dawley rats weighing 300-400 g (Charles River, Kingston, NY, USA) were used for the synaptosome assays. Rats were group-housed in a temperature (22.2 ± 1.1 °C) and humidity (45 ± 10%) controlled room under a standard 12 h light/dark cycle (lights on at 0700 h), with free access to food and water. Rats were euthanized by CO₂ narcosis, synaptosomes were prepared from brain tissue, and transporter release assays were performed as described previously (Rothman et al., 2001; Baumann et al., 2013; Solis et al., 2017). In brief, synaptosomes were prepared from caudate tissue for DAT assays, whereas synaptosomes were prepared from whole brain minus caudate and cerebellum for NET and SERT assays. For release assays, 9 nM [³H]MPP⁺ was used as the radiolabeled substrate for DAT and NET, while 5 nM [³H]5-HT was used for SERT. All buffers used in the release assay contained 1 μM reserpine to block vesicular uptake of substrates. The selectivity of release assays was optimized for a single transporter by including unlabeled blockers to prevent the uptake of [³H]MPP⁺ or [³H]5-HT by competing transporters. Synaptosomes were preloaded with radiolabeled substrate in Krebs-phosphate buffer for 1 h to achieve steady state. Release assays were initiated by incubating preloaded synaptosomes with various concentrations of test drugs. Release was terminated by vacuum filtration, and retained radioactivity was quantified by liquid scintillation counting.

In order to verify that drug-induced release of [³H]MPP⁺ from synaptosomes was mediated by DAT or NET, we conducted “substrate reversal” experiments. For substrate reversal studies, synaptosome release assays were conducted as described above in the presence or absence of a fixed concentration of 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909, 1 nM) or desipramine (8 nM) to block DAT or NET, respectively. Previous findings demonstrate that co-incubation of uptake blockers with releasers at DAT or NET will produce parallel rightward shifts in the release curves for true transporter substrates (Rothman et al., 2001). Effects of test drugs on release were expressed as % maximum
release, with maximum release (i.e., 100% E\text{max}) defined as the release produced by tyramine at doses that evoke the efflux of all ‘releasable’ tritium by synaptosomes (10 µM tyramine for DAT and NET assay conditions, and 100 µM tyramine for SERT assay conditions). Effects of test drugs on release were analyzed by nonlinear regression using GraphPad Prism V6 (GraphPad Scientific, San Diego, CA, USA), with dose–response data fit to the equation, \( Y(x) = Y_{\text{min}} + (Y_{\text{max}} - Y_{\text{min}}) / (1 + 10^{\exp[(\log P_{50} - \log x) \times n]}) \), where \( x \) is the concentration of the compound tested, \( Y(x) \) is the response measured, \( Y_{\text{max}} \) is the maximal response, \( P_{50} \) is EC\text{50} (the concentration that yields half-maximal release), and \( n \) is the Hill slope parameter.

\textit{In vitro receptorome screening in transfected cells}

BMPEA and its analogs were submitted to the Psychoactive Drug Screening Program (PDSP) of the National Institute on Mental Health and evaluated for binding activity at various human GPCRs transfected in cells, according to established protocols (Besnard et al., 2012). In particular, the activity of test drugs at receptor subtypes for dopamine, norepinephrine, 5-HT, histamine, and opioids were examined. Compounds were first screened at a fixed concentration of 10 µM to assess inhibition of receptor binding. In those instances where binding was inhibited by more than 50% at 10 µM, full dose-response curves were obtained, and Ki values (nM) were calculated by non-linear regression using the Cheng-Prusoff equation.

\textit{In vivo biotelemetry in rats}

A total of 12 adult male Sprague-Dawley rats weighing 300–400 g (Charles River, Kingston, NY, USA) rats were used as subjects. Rats were purchased by Data Sciences International (DSI, St. Paul, MN, USA) and subsequently received surgically-implanted intraperitoneal (i.p.) HD-S10 biotelemetry transmitters to measure changes in BP, HR, activity and temperature. Surgery was
carried out by experienced technicians at DSI. For the surgery, rats were anesthetized with isoflurane and the abdominal cavity opened. The descending aorta was isolated, and the catheter from the transmitter was inserted into the aorta and glued in place. The abdominal muscles and skin were then closed. Rats were treated with subcutaneous (s.c.) meloxicam following surgery. After recovery from surgery at DSI, the rats were shipped to NIDA/IRP in Baltimore, MD, and underwent a 7-day quarantine.

Following release from quarantine, the rats were individually-housed in a temperature (22.2 ± 1.1 °C) and humidity (45 ± 10%) controlled room under a 12 h reverse light-dark cycle (lights off at 0700 h) with free access to water. Food was restricted to maintain a constant or slowly increasing weight of approximately 400-500 gm over the course of the experiments. Rats were subsequently adapted to the experimental chambers and injection procedure over a period of 3-4 weeks. Each weekday the rats were transported to the procedure room, where food and water were removed from the home cage, and the entire home cage was placed on top of a telemetry receiver (RPC-001, Data Sciences) inside a small acoustical chamber (BRS/LVE, Laurel, MD, USA). Transmitters were turned on by placing a magnet near the abdomen of the rat. The chambers were then closed, and experimental parameters were monitored for 3 h. At the end of the session, the transmitters were turned off by again placing a magnet near the abdomen of the rats, food and water were replaced to the home cage, and the rats were returned to the housing room. Once experimental parameters were stable from day to day, injections of saline were given s.c. at least twice per week (typically on Tuesdays and Fridays) 5 min prior to the rats being placed in the experimental chamber. Once experimental parameters in response to saline injection were again stable, experimental procedures with test drugs commenced.

Dose-effect determinations for BMPEA (3 – 30 mg/kg), MPPA (3 – 30 mg/kg), DMPPA (3 – 30 mg/kg) and amphetamine (0.1 – 3 mg/kg) were determined in 7 rats. These rats had
previously been tested with combinations of 3,4-methylenedioxypyrovalerone (MDPV) and chlorisondamine, prazosin or propranolol for prior experiments (Schindler et al., 2016); some rats had also received synthetic cannabinoids (Schindler et al. 2017) or α-pyrrolidinovalerophenone. Sufficient washout time of greater than 4 weeks was allowed between prior testing and the current testing to avoid drug interactions. Order for the dose-effect testing was non-systematic, although all rats were typically tested with the same drug and dose on any given test day. All drugs were administered s.c. 5 min prior to placement of the rat in the experimental chamber. Saline was tested every 2-3 weeks and responses following saline were stable over the testing period.

Five additional rats were tested with combinations of prazosin (0.3 mg/kg) or chlorisondamine (1 mg/kg) and BMPEA (30 mg/kg). These rats had previously been tested with α-ethyl-phenethylamine (AEPEA). As with dose-effect testing, a minimum 4-week washout period was allowed for the effects of AEPEA to dissipate and not interact with current testing. Order of testing was identical to that described for dose-effect testing. Prazosin was administered s.c. 5 min prior to BMPEA that was given 5 min prior to placement in the chamber. Chlorisondamine was given s.c. 10 min prior to BMPEA. Appropriate controls for pretreatment alone and vehicle alone were tested for both prazosin and chlorisondamine. The effects of 30 mg/kg BMPEA alone were similar to the separate group of rats in the dose-effect group. In addition, 30 mg/kg BMPEA was tested twice in the pretreatment group about 4 months apart and produced similar results in each test, indicating that there were no long-term effects of the drugs that could alter the results.

Data from biotelemetry transmitters were collected for 10 sec epochs every min and these 1-min readings were averaged over the first h for statistical analysis. The transmitters supplied readings for BP (i.e., mean arterial pressure), HR (derived from the BP signal), temperature and
motor activity. Motor activity was measured by tracking the strength of the transmitter radio signal as the rat moved about the home cage, so these measures do not have any units. Dose-effect data for each drug were subjected to analysis-of-variance (ANOVA, Prism V6) followed by Dunnett’s Multiple Comparison Test that can compare drug effects to control. Data for the drug interaction studies were also subject to ANOVA, with follow-up Tukey’s Multiple Comparison Test that allows for comparisons between all groups tested.

Results

In vitro transporter release assays in synaptosomes

Figure 2 shows dose-effect curves for drug-induced efflux (i.e., release) of [3H]MPP+ at DAT (upper panels) and NET (lower panels), with the calculated EC50 and %E{\text{max}} values shown in Table 1. As expected, amphetamine and methamphetamine were potent substrate-type releasers at both DAT and NET. Dimethylamphetamine was a much less potent releaser than amphetamine at DAT and somewhat less potent at NET, leading to a preference for NET over DAT. It is noteworthy that dimethylamphetamine displayed partial releasing activity at DAT, reaching only 78% of E{\text{max}} values. Amphetamine and methamphetamine were weak releasers at SERT, while dimethylamphetamine was inactive at this transporter at concentrations up to 10 μM (data not shown). BMPEA and MPPA produced full-efficacy release at DAT but were >50-fold less potent when compared to amphetamine and methamphetamine in this regard. DMPPA was completely inactive as a substrate at DAT. BMPEA and MPPA were full-efficacy releasers at NET, while DMPPA was a weak partial releaser (i.e., 67% E{\text{max}}) at this transporter. BMPEA, MPPA and DMPPA were about 10-fold less potent than amphetamine and its analogs as substrates at NET. It is noteworthy that BMPEA, MPPA and DMPPA showed a clear preference
for NET over DAT, and none of the compounds were substrates at SERT at concentrations up to 10 µM.

Figure 3 shows the effects of an uptake inhibitor at DAT (GBR12909) or NET (desipramine) on amphetamine- and BMPEA-induced release of [3H]MPP⁺ from rat brain synaptosomes. Co-incubation with GBR12909 produced a parallel rightward shift in the DAT-mediated release curves for amphetamine (6.2-fold increase in EC₅₀) and BMPEA (4.7-fold increase in EC₅₀). GBR12909 had a comparable effect on the releasing activity of MPPA (4.6-fold increase in EC₅₀). The findings with GBR12909 indicate that amphetamine, BMPEA and MPPA exert their releasing actions at DAT by interacting competitively with a binding site blocked by GBR12909. In a similar manner, co-incubation with desipramine shifted the NET-mediated release curves for both amphetamine (3.8-fold increase in EC₅₀) and BMPEA (5.7-fold increase in EC₅₀). Desipramine also produced a rightward shift in the release curves for MPPA (4.1-fold shift) and DMPPA (4.4-fold shift)(data not shown). The results with desipramine indicate that amphetamine, BMPEA, and its analogs, exert their releasing actions at NET by interacting competitively with a binding site blocked by desipramine.

In vitro receptorome screening in transfected cells

Table 2 presents the results for BMPEA, MPPA and DMPPA in the GPCR screening in comparison to amphetamine. In general, BMPEA and its analogs had little activity at GPCRs when tested at a 10 µM concentration. Specific exceptions included the 5-HT₁A receptor where BMPEA and MPPA had mid-nM affinities (375-915 nM); alpha2 receptor subtypes where BMPEA showed affinities in the range of its transporter releasing potency (288-1739 nM); and the Sigma-1 receptor where MPPA and DMPPA showed low µM affinities. BMPEA and its analogs also had low µM affinities to inhibit binding to the Sigma-2 site. Interestingly, none of
the BMPEA analogs potently inhibited binding to DAT, NET or SERT. While this finding seems counterintuitive, previous studies demonstrate that amphetamine and other monoamine transporter substrates display very weak ability to displace high-affinity ligands in binding assays for DAT, NET and SERT (Eshelman et al., 1999; Rothman et al., 1999; Eshleman et al., 2017).

In vivo biotelemetry in rats

In general, the rats with surgically-implanted telemetry transmitters adapted quickly to the experimental procedure, and results for the control conditions remained stable throughout testing. Importantly, there was no indication that previous drug treatments altered the baseline for any of the parameters reported in the present study. Following s.c. vehicle injections, BP and HR values were slightly elevated immediately after placement of the rats into the experimental chamber but declined over the first 60 min and remained steady until the end of the session (Figure 4).

Figure 4 shows the time-course for the effects of amphetamine and BMPEA on BP (upper panels) and HR (lower panels) in conscious rats. Amphetamine produced dose-dependent increases in both parameters that were sustained throughout the 3 h session. BMPEA also produced a dose-dependent increase in BP, but the effects dissipated throughout the session, and by the end of the 3 h, had returned to the saline control level. The effects of BMPEA on HR were more complicated, with small increases observed at the lower doses and the highest dose producing a substantial decrease. Again, the effects of BMPEA were mostly restricted to the first h of the session. Because the most prominent effects of BMPEA were in the beginning of the session, the analysis of mean effects presented below is based only on the first h of measurements.
As depicted in Figure 5, amphetamine produced significant dose-dependent increases in mean BP (F_{4,34} = 20.9, p < 0.001) and HR (F_{4,34} = 11.1, p < 0.001). Amphetamine also produced significant increases in motor activity (F_{4,34} = 9.4, p < 0.001), although this effect peaked at 1 mg/kg and the higher dose failed to produce a significant increase in activity. This decrease in motor activity at the highest amphetamine dose could be due to the tendency for this drug, and other psychomotor stimulants, to produce in-place stereotypy at higher doses that the telemetry system does not detect. Amphetamine did not produce significant changes in temperature.

While less potent than amphetamine, BMPEA also dose-dependently increased BP (F_{3,27} = 15.0, p < 0.001). MPPA produced hypertensive effects similar to, or even greater than, BMPEA (F_{3,27} = 20.8, p < 0.001). While DMPPA also tended to increase BP compared to saline control, this effect failed to reach significance. In contrast to the clear dose-dependent effects of amphetamine on HR, the cardiac effects of the other compounds were less uniform. BMPEA slightly decreased HR at the highest dose (F_{3,27} = 6.7, p < 0.01), while MPPA slightly increased HR at the two lowest doses (F_{3,27} = 5.5, p < 0.01). DMPPA did not significantly affect HR. In striking contrast to amphetamine, none of the other drugs tested affected motor activity.

BMPEA slightly decreased body temperature at the two highest doses (F_{3,27} = 8.9, p < 0.001). To summarize, all four drugs produced significant and dose-dependent increases in BP. However, in contrast to the robust effects of amphetamine on HR and activity, BMPEA and its analogs produced small variable effects on HR and no significant stimulation of motor activity. Only BMPEA affected body temperature, with a small decrease that was restricted to the first h of the session.

Because BMPEA is frequently encountered in pre-workout and weight loss supplements, and its most prominent effect was on the cardiovascular system, we next determined whether the ganglionic blocker chlorisondamine or the α-adrenergic antagonist prazosin could antagonize
those effects. Figure 6 shows the effects of pretreatment with 1 mg/kg chlorisondamine or 0.3 mg/kg prazosin on BP (upper panels) and HR (lower panels) changes induced by 30 mg/kg BMPEA. As in the dose-effect determination, 30 mg/kg BMPEA significantly increased BP ($F_{3,19} = 114.6, p < 0.001$ for chlorisondamine graph; $F_{3,19} = 32.9, p < 0.001$ for prazosin graph). The hypertensive effect of BMPEA was not antagonized by chlorisondamine, even though chlorisondamine alone decreased BP, suggesting a peripheral site of action for BMPEA. BMPEA alone produced a small decrease in HR for the chlorisondamine tests ($F_{3,19} = 99.83, p < 0.001$); however, when pretreated with chlorisondamine, that HR decrease was converted to a significant tachycardia, even though chlorisondamine on its own had no effects on HR. The hypertensive effects of BMPEA was completely antagonized by prazosin, indicating the BP increase is mediated via the sympathetic nervous system. For HR, prazosin alone produced tachycardia ($F_{3,19} = 31.76, p < 0.01$). When administered after prazosin, BMPEA increased HR over saline, however this effect was no different than prazosin alone complicating interpretation of the result.

**Discussion**

BMPEA and related compounds continue to be detected as adulterants in pre-workout and weight loss supplements, despite being banned by the FDA (Cohen et al., 2106; Eichner et al., 2016; Rasmussen and Keizers, 2016). The main objective of the present work was to examine the pharmacology of BMPEA and its $N$-methylated analogs, MPPA and DMPPA. Because BMPEA is a structural isomer of amphetamine, we reasoned that the compounds might share similar mechanisms of action and pharmacological profiles *in vivo*. Findings from our *in vitro* transporter release assays confirm that amphetamine and methamphetamine are potent substrate-type releasers at DAT and NET, with much weaker activity at SERT (Rothman et al., 2001;
Rothman and Baumann, 2003). Similar to amphetamine, BMPEA also acted as a substrate-type releaser at DAT and NET, but showed a clear preference for NET over DAT. In contrast to amphetamine, BMPEA was inactive in the SERT release assay at concentrations up to 10 µM. For both amphetamine and BMPEA, co-incubation with the dopamine uptake inhibitor GBR12909 shifted the dose-effect curve for DAT-mediated $[^3]H$MPP$^+$ efflux to the right in a parallel manner (i.e., increased EC$_{50}$ values), indicating a decrease in releasing potency. Likewise, the norepinephrine uptake inhibitor desipramine shifted the dose-effect curve for NET-mediated release to the right. Data from the “substrate reversal” experiments provide compelling evidence that BMPEA and its analogs interact with the orthosteric binding site on DAT and NET to exert their neurotransmitter releasing actions, analogous to the mechanism of action for amphetamine and its analogs (Rothman and Baumann, 2003; Reith et al., 2015; Sitte and Freissmuth 2015).

BMPEA failed to inhibit radioligand binding to DAT or NET, and this observation is consistent with prior studies demonstrating that substrate-type releasing drugs display weak ability to displace high-affinity ligands in transporter binding assays (Rothman et al., 1999; Simmler et al., 2013; Eshleman et al., 2017). However, the present NET binding results illustrate an important difference between amphetamine and BMPEA. Previous studies show that amphetamine displays a Ki value of ~4 µM for NET sites labeled with the cocaine analog $[^{125}]$RTI-55 (Eshleman et al., 1999) whereas we report a Ki value of 30 nM for NET sites labeled with $[^3]H$nisoxetine. Thus, the $[^3]H$nisoxetine binding assay uncovers a substantial affinity difference between amphetamine and BMPEA that is not mirrored in the release assays. One interpretation of these data is that amphetamine and BMPEA might interact with the NET protein in a somewhat different manner to exert their effects, and future studies should investigate this possibility.
From a structure-activity perspective, we found that adding steric bulk to the terminal amine of amphetamine or BMPEA produced notable changes in functional measures of transporter activity. For example, adding a single methyl group to amphetamine (i.e., methamphetamine) had minimal influence on releasing potency at DAT or NET, while adding a second methyl group (i.e., dimethylamphetamine) markedly decreased releasing potency in both assays. Likewise, for BMPEA, adding one methyl group to the terminal amine (i.e., MPPA) had minimal effect on releasing potency at DAT or NET. However, adding a second methyl group (i.e., DMPPA) produced a dramatic decrease in releasing potency at NET and a complete loss of releasing activity at DAT. The present findings with BMPEA and its N-methylated analogs are generally consistent with previous results that show N-ethyl derivatives of amphetamines or β-keto amphetamines (i.e., cathinones) display substrate activity at NET but markedly reduced or absent substrate activity at DAT (Saha et al., 2015; Solis et al., 2017). The preference of BMPEA and its analogs for NET over DAT suggests that these compounds may not be abused to a significant degree. It is well established that the abuse potential of stimulant drugs is related to their ability to increase extracellular concentrations of dopamine in the brain (Rothman and Baumann, 2003; Sitte and Freissmuth, 2015; Volkow et al., 2017). On the other hand, the preference of BMPEA and its analogs for NET infers a risk for cardiovascular side effects similar to those produced by amphetamines.

In our telemetry experiments, amphetamine produced clear, dose-dependent and sustained increases in BP and HR, in agreement with previous results (Broadley, 2010; Varner et al., 2013). BMPEA and MPPA produced robust dose-dependent increases in BP similar in magnitude to the effects of amphetamine but were about 10-fold less potent than amphetamine. While trending in the direction of an increase, the hypertensive effect of DMPPA was not statistically significant. In contrast to amphetamine, the effects of BMPEA and its analogs on HR
were complex. BMPEA produced a significant, albeit small, decrease in HR at the highest dose, while lower doses tended to increase HR. MPPA slightly increased HR at lower doses while DMPAA did not. It is noteworthy that cardiovascular perturbations produced by BMPEA, MPPA and DMPAA were brief when compared to effects of amphetamine, suggesting that β-methyl compounds are metabolized or eliminated rapidly after systemic administration. Pretreatment with the ganglionic blocker chlorisondamine did not reverse the hypertensive effect of BMPEA, despite the fact that chlorisondamine alone produced hypotension. This result demonstrates that effects of BMPEA on BP do not involve a central mechanism but are mediated peripherally. Further supporting this conclusion, chlorisondamine pretreatment converted BMPEA-induced bradycardia to marked tachycardia. This intriguing observation suggests BMPEA actually produces a peripherally-mediated increase in HR that is normally counteracted by a centrally-mediated baroreceptor reflex to decrease HR. Finally, the α1-adrenoreceptor antagonist prazosin blocked the hypertensive effects of BMPEA, indicating this response involves activation of the sympathetic nervous system. Taken together with the findings in synaptosomes, the telemetry results suggest that BMPEA and its analogs increase BP by a mechanism involving transporter-mediated release of norepinephrine from peripheral stores, which then activates α1-adrenoreceptors in vascular tissue.

Extrapolation of preclinical results from rats to humans is always problematic due to a number of different factors. For example, we administered BMPEA to rats by the s.c. route whereas humans take BMPEA by the oral route. Nevertheless, controlled clinical studies demonstrate that 20 mg of oral amphetamine (i.e., 0.29 mg/kg for a 70 kg subject) increases BP in human volunteers (Sofuoglu et al., 2009; Wardle and de Wit, 2012), and we show similar effects after 0.3 mg/kg of s.c. amphetamine in rats (Figures 4 and 5). Such observations indicate that our in vivo preclinical data might be directly translatable to humans. With regard to
BMPEA, we found this compound to be 10-fold less potent than amphetamine in its ability to increase BP in rats. Given that 290 mg of BMPEA is a reported oral dose in humans (Cohen et al., 2015), it seems feasible that this amount of BMPEA could elevate BP. Future clinical studies are warranted to investigate the cardiovascular effects of BMPEA and related compounds.

It is important to consider the possibility that BMPEA, MPPA and DMPPA might act at non-transporter sites of action, most notably GPCRs, to produce their effects on BP. Assuming these drugs are acting at the same site to produce their effects on BP, then one can assume that their rank order of potency at a given site of action would parallel their order of potency to produce hypertension (BMPEA = MPPA > DMPPA). BMPEA showed weaker affinity than DMPPA at the Sigma-1 receptor, which likely rules out this site as a potential target. At the Sigma-2 receptor, BMPEA and DMPPA were equipotent but displayed lower Ki values than MPPA, again suggesting this site is not involved with hypertensive effects of BMPEA and its analogs. BMPEA had mid-nM affinities at subtypes of α2-adrenoreceptors, and these sites can modulate BP (c.f. van Zwieten, 1999). However, the fact that MPPA had equal or greater effects on BP than BMPEA, but was inactive at α2-adrenoreceptor subtypes, appears to rule out a role for these sites in the BP changes observed. Finally, BMPEA and MPPA had similar affinity for the 5-HT1A receptor. Actions at the 5-HT1A receptor can also influence BP (Anderson et al., 1992; Ramage and Villalon, 2008) but DMPPA had virtually no affinity for 5-HT1A receptors yet still produced increases in BP. Therefore, it seems reasonable to assume that BMPEA and its analogs produce increases in BP via a mechanism which relies on peripheral NET sites rather than direct actions at GPCRs.

We found that amphetamine produced dramatic increases in locomotor activity, a characteristic of abused psychomotor stimulants (Rothman and Baumann, 2003; Sitte and Friessmuth, 2015). The highest dose of amphetamine did not produce an increase in locomotor
activity, which likely reflects an increase in focused in-place stereotypies at this dose. Although not measured directly here, an increase in stereotypy at higher doses is typical of psychomotor stimulants (c.f. Wolgin, 2012), and the small repetitive movements associated with stereotypy may not be detected by the telemetry system used here. BMPEA and its analogs failed to produce significant changes in motor activity. This result may be related to the relatively weak effects of these compounds at DAT compared to NET but may also reflect poor penetration of the compounds across the blood-brain-barrier. The fact that these compounds do not increase motor activity like most stimulant drugs of abuse supports the contention mentioned above that BMPEA, MPPA and DMPPA may not exhibit significant abuse potential. Neither amphetamine nor BMPEA analogs had robust effects on body temperature at doses tested here. Only BMPEA produced a significant decrease in body temperature, and this effect was only 0.5 °C, well within the normal variance of body temperature under physiological conditions. Thus, it appears that these compounds do not substantially affect core body temperature regulation, at least when the animals are kept at room temperature.

In summary, the findings presented here demonstrate that BMPEA and its analogs produce transient dose-dependent increases in BP that resemble the effects of amphetamine. Converging lines of evidence indicate that hypertensive effects are mediated through the peripheral sympathetic nervous system, most likely by substrate-type releasing actions at NET. BMPEA and related compounds show a distinct preference for releasing activity at NET over DAT, and do not produce motor activation, suggesting the compounds will have minimal abuse potential. On the other hand, since these analogs are still being found in pre-workout and weight loss supplements that are not routinely tested for safety (Cohen et al., 2016; Eichner et al., 2016; Rasmussen and Keizers, 2016), the risk for cardiovascular side-effects remains a possibility in vulnerable individuals. Future studies should examine the pharmacology and toxicology of other
amphetamine-related compounds that are present as adulterants in supplements (e.g., N,α-diethylphenethylamine), as consumers are being unknowingly exposed to these substances.
Authorship Contributions

Participated in research design: Schindler and Baumann

Conducted experiments: Schindler, Thorndike, Partilla and Baumann

Contributed new reagents: Rice

Performed data analysis: Schindler, Thorndike and Baumann

Wrote or contributed to writing of manuscript: Schindler, Rice and Baumann
References


Cohen PA, Bloszies C, Yee C, & Gerona R (2016). An amphetamine isomer whose efficacy and safety in humans has never been studied, beta-methylphenylethylamine (BMPEA), is found in multiple dietary supplements. Drug Test Anal 8: 328-333.


Footnote

This research was supported by the Intramural Research Program of the National Institute on Drug Abuse (NIDA) and the National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH).
Legends for Figures

Figure 1. Chemical structures of amphetamine and BMPEA analogs examined in this study.

Figure 2. Concentration-response effects for analogs of amphetamine (AMPH) and BMPEA to stimulate \[^3\text{H}\text{MPP}^+\] efflux (i.e., release) via the dopamine transporter (DAT, upper panels) or norepinephrine transporter (NET, lower panels). Rat brain synaptosomes were preloaded with 9 nM \[^3\text{H}\text{MPP}^+\] and different concentrations of AMPH, methamphetamine (METH), dimethylamphetamine (DIMETH), BMPEA, MPPA or DMPPA were added to stimulate release. Results are plotted as a percent of maximal release elicited by 10 µM tyramine. Data are mean±SD for N=3 separate experiments performed in triplicate.

Figure 3. Concentration-response effects for amphetamine (AMPH) and BMPEA to stimulate \[^3\text{H}\text{MPP}^+\] efflux (i.e., release) in the presence or absence of the DAT blocker GBR12909 (GBR, upper panels) or the NET blocker desipramine (DMI, lower panels). Rat brain synaptosomes were preloaded with 9 nM \[^3\text{H}\text{MPP}^+\] and different concentrations of AMPH or BMPEA were added to stimulate release in the presence or absence of 1 nM GBR12909 for DAT assays or 8 nM desipramine for NET assays. Data are mean±SD for N=3 separate experiments performed in triplicate.

Figure 4. Time-course effects of amphetamine (AMPH) and BMPEA to influence blood pressure (BP, upper panels) and heart rate (HR, lower panels) in conscious rats bearing biotelemetry transmitters. Rat received s.c. injections AMPH or BMPEA and were subsequently moved to
recording chambers for 3 h test sessions. Mean values for N=7 rats/group are plotted for 1-min epochs over the entire 180 min sampling period.

Figure 5. Dose-effect functions for amphetamine (AMPH), BMPEA, MPPA and DMPPA on blood pressure (BP), heart rate (HR), motor activity and body temperature. Data are mean values from the first h of test sessions, where the effects of the test drugs were maximal. Solid symbols indicate significant differences compared to the respective saline control group. Data are mean±SEM for N=7 rats/group.

Figure 6. Effects of pretreatment with the ganglionic blocker chlorisondamine (1 mg/kg, s.c.) or the α1-adrenoreceptor antagonist prazosin (0.3 mg/kg, s.c.) on blood pressure (BP, upper panels) or heart rate (HR, lower panels) produced by 30 mg/kg BMPEA. Data are mean±SEM from the first h of the sessions, where the effects of BMPEA were maximal, N=5 rats/group. Filled bars represent a significant difference from saline + saline (Sal + Sal). * Indicates a significant difference from BMPEA alone (Sal or Veh + BMPEA 30).
### Tables

#### Table 1. Effects of amphetamine, BMPEA and their respective analogs on release of $[^3H]MPP^+$ at DAT and NET in rat brain synaptosomes

<table>
<thead>
<tr>
<th>Drug</th>
<th>Release at DAT $EC_{50}$ (nM) [% $E_{max}$]</th>
<th>Release at NET $EC_{50}$ (nM) [% $E_{max}$]</th>
<th>DAT/NET ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine</td>
<td>$5 \pm 1$ [104]</td>
<td>$9 \pm 2$ [95]</td>
<td>1.80</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>$7 \pm 2$ [108]</td>
<td>$16 \pm 3$ [97]</td>
<td>2.29</td>
</tr>
<tr>
<td>Dimethylamphetamine</td>
<td>$1250 \pm 231$ [78]</td>
<td>$223 \pm 40$ [84]</td>
<td>0.18</td>
</tr>
<tr>
<td>BMPEA</td>
<td>$627 \pm 102$ [101]</td>
<td>$126 \pm 21$ [94]</td>
<td>0.20</td>
</tr>
<tr>
<td>MPPA</td>
<td>$574 \pm 52$ [103]</td>
<td>$154 \pm 25$ [80]</td>
<td>0.27</td>
</tr>
<tr>
<td>DMPPA</td>
<td>inactive</td>
<td>$1337 \pm 354$ [67]</td>
<td>----</td>
</tr>
</tbody>
</table>

Data are mean ± SD for N=3 experiments performed in triplicate. % $E_{max}$ is defined as % of maximal releasing response induced by 10 µM tyramine. DAT/NET ratio = $(DAT IC_{50}^{-1})/(NET IC_{50}^{-1})$; higher value indicates greater DAT selectivity.
Table 2. G protein-coupled receptor screening for amphetamine, BMPEA and its analogs

<table>
<thead>
<tr>
<th>Receptor Family</th>
<th>AMPH</th>
<th>BMPEA</th>
<th>MPPA</th>
<th>DMPPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serotonin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-HT1A</td>
<td>2,625</td>
<td>375</td>
<td>915</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>5-HT1B</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>5-HT1D</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>5-HT1E</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>5-HT2A</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>5-HT2B</td>
<td>971</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>5-HT2C</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>SERT</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha1A</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Alpha1B</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Alpha1D</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Alpha2A</td>
<td>420</td>
<td>1,739</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Alpha2B</td>
<td>192</td>
<td>288</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Alpha2C</td>
<td>171</td>
<td>962</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Beta1</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Beta2</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Beta3</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>NET</td>
<td>31</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Dopamine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D1</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>D2</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>D3</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>D4</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>D5</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>DAT</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Sigma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sigma 1</td>
<td>&gt;10,000</td>
<td>&gt;10,000</td>
<td>1,233</td>
<td>1,636</td>
</tr>
<tr>
<td>Sigma 2</td>
<td>&gt;10,000</td>
<td>2,735</td>
<td>8,110</td>
<td>2,802</td>
</tr>
</tbody>
</table>

Data represent Ki (nM) values obtained from non-linear regression using the Cheng-Prusoff equation when inhibition of binding at 10 µM was above 50%.
Figures

Amphetamine

Methamphetamine

Dimethylamphetamine

β-methylphenethylamine (BMPEA)

N-Methyl-2-phenylpropan-1-amine (MPPA)

N,N-Dimethyl-2-phenylpropan-1-amine (DMPPA)

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6